Ajanta Pharma Q1 Results FY26: Q1 PAT Rose 3.89% to ₹255.34 Crore; Revenue Surged 13.78% YoY

Ajanta Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹1,302.65	₹1,144.92
Profit Before Tax (PBT)	₹377.68	₹356.82
Profit After Tax (PAT)	₹255.34	₹245.77

(Figures in crores)

Ajanta Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹1,208.56	₹1,077.27
Profit Before Tax (PBT)	₹370.03	₹344.2
Profit After Tax (PAT)	₹254.97	₹236.03

(Figures in crores)

Ajanta Pharma Results FY26 Highlights (Q1 FY26 vs FY25)

• Ajanta Pharma clocked Q1 FY26 consolidated revenue of ₹1,302.65 crores vs ₹1,144.92 crores. 
• On the profit front, Ajanta Pharma earned a consolidated PAT of ₹255.34 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹245.77 crore. 
• Consolidated PAT rose for the first quarter of FY26, was 3.89% YoY, and revenue rose 13.78% YoY. 
• As per the standalone figures, the quarterly PAT of Ajanta Pharma has increased by 8.02% and revenue has increased by 12.19% YoY.

Ajanta Pharma Share Price Performance

On the opening bell of 28th July 2025, the shares of Ajanta Pharma opened at ₹2794.00 per share. However, the initial gains are wiped out as of now, and Ajanta Pharma shares are trading at ₹2751.60 per share, lower than their opening price. 

Considering the long-term performance, Ajanta Pharma shares have yielded close to 13.77% returns in the past 1 year, and 5-year returns stand at 153.34%. Over the maximum timeframe, the  Ajanta Pharma share provided 17,348.32% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Ajanta Pharma shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Also Read : Aditya Birla Sun Life AMC Q1 Results FY26: Q1 PAT Rise 17.56% to ₹277.11 crore; Revenue Surged 15.72% YoY

Recent Articles

Aditya Infotech IPO GMP & Review: Apply or Avoid?

Hfcl Q1 Results FY26: Q1 PAT Fall 128.97% to ₹-32.25 Crore; Revenue decline 24.80% YoY

Bank of Baroda Q1 Results FY26: Q1 PAT Fall 26.62% to ₹3,469.16 crore; Revenue Surged 7.27% YoY

Shree Refrigerations IPO GMP: Day 1 IPO Live Updates

Patel Chem Industries IPO GMP: Day 1 IPO Live Updates

Sellowrap Industries IPO GMP: Day 1 IPO Live Updates

Shanti Gold IPO GMP: Day 1 IPO Live Updates